Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance Ann Rheum Dis 2022 Sep 22. pii: ard-2022-222259. doi: 10.1136/ard-2022-222259.
PMID: 36137735